000			nab a22 7a 4500
999			_c16676 _d16676
003			PC16676
005			20211129121045.0
008			211129b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9431 _aGrávalos Castro, Cristina _eOncología Médica
245	0	0	_aTTD consensus document on the diagnosis and management of exocrine pancreatic cancer. _h[revisión]
260			_bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of México. _c2014
300			_a16(10):865-78.
500			_aFormato Vancouver: Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J et al. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol. 2014 Oct;16(10):865-78.
501			_a PMID: 24728654
504			_aContiene 121 referencias
520			_aExocrine pancreatic cancer (PC) is a very aggressive and heterogeneous tumor with several cellular signaling pathways implicated in its pathogenesis and maintenance. Several risk factors increase the risk of developing PC. Therapeutic strategies used are dictated by the extent of disease. Supportive treatment is critical because of the high frequency of symptoms. For localized disease, surgery followed by adjuvant gemcitabine is the standard. Neoadjuvant and new adjuvant chemotherapy regimens are being evaluated. Locally advanced disease should respond best guided by a multidisciplinary team. Various treatment options are appropriate such as chemotherapy alone or chemoradiotherapy with integration of rescue surgery if the tumor becomes resectable. In metastatic disease, chemotherapy should be reserved for patients with ECOG 0-1 using Folfirinox or gemcitabine plus nab-paclitaxel as the most recommended options. Several therapeutic strategies targeting unregulated pathways are under evaluation with an unmet need for biomarkers to guide management.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16676.pdf _ySolicitar documento
942			_2ddc _cREV _n0